Medical Condition News

RSS

Promising results from Exelixis' cabozantinib phase 2 trial against metastatic ovarian cancer

Exelixis, Inc. reported longer follow-up data from a fully enrolled cohort of patients with advanced epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube carcinoma treated with cabozantinib (XL184) in an ongoing phase 2 adaptive randomized discontinuation trial. Cabozantinib shows promising activity in these patients independent of prior response to platinum-based therapies.

6 Jun 2011

ImaginAb, GE Healthcare sign master research deal to develop new PET diagnostic imaging agents

GE Healthcare Ltd. and ImaginAb, Inc. have executed a master research agreement around the development of new PET (Positron Emission Tomography) diagnostic imaging agents based on ImaginAb's antibody fragment technology. The agreement is launched with an initial exclusive collaboration around a novel cardiovascular target.

6 Jun 2011

GP journal focuses on mental health

Australian Family Physician, the flagship journal of The Royal Australian College of General Practitioners (RACGP), features a range of clinical, viewpoint and research articles focusing on key issues in general practice today. The June 2011 edition focuses on mental illness and includes the following feature articles.

6 Jun 2011

Older adults with subclinical hyperthyroidism may face higher risk of dying

A common hormone abnormality in older adults—a mild form of overactive thyroid called subclinical hyperthyroidism—is linked to a much higher risk of dying, a new study finds. The results will be presented Sunday at The Endocrine Society's 93rd Annual Meeting in Boston.

6 Jun 2011

ImmunoGen's SAR3419 Phase I trial data on B-cell non-Hodgkin's lymphoma presented at ASCO 2011

ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced the presentation of favorable clinical data for SAR3419 in the treatment of B-cell non-Hodgkin's lymphoma (NHL).

6 Jun 2011

Brown fat can treat obesity and diabetes

A new study suggests that many adults have large amounts of brown fat, the "good" fat that burns calories to keep us warm, and that it may be possible to make even more of this tissue.

6 Jun 2011

Alnylam's ALN-VSP Phase I trial data on liver cancer presented at ASCO 2011

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the results from its Phase I clinical trial with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement.

6 Jun 2011

Nonmenstruating female athletes have abnormal bone structure: Study

Young female athletes who have stopped menstruating have a weakening in the quality of their bone structure that may predispose them to breaking a bone, despite getting plenty of weight-bearing exercise, a new study finds. The results will be presented Sunday at The Endocrine Society's 93rd Annual Meeting in Boston.

6 Jun 2011

$Bariatric weight-loss surgery may increase risk of fractures$

Bariatric weight-loss surgery may increase risk of fractures

People who have had gastric bypass surgery or other bariatric weight-loss surgery have an even higher increased risk of breaking bones than previously found. These study findings will be presented Tuesday at The Endocrine Society's 93rd Annual Meeting in Boston.

6 Jun 2011

Anti-ghrelin vaccine decreases food intake and increases calorie burning in mice

A new therapeutic vaccine to treat obesity by suppressing the appetite-stimulating hormone ghrelin decreases food intake and increases calorie burning in mice, a new study finds. The results will be presented Sunday at The Endocrine Society's 93rd Annual Meeting in Boston.

6 Jun 2011

Positive results from Plexxikon's vemurafenib Phase 2 and 3 trial against metastatic melanoma

Plexxikon Inc., a member of the Daiichi Sankyo Group, today announced efficacy and safety data from the BRIM3 trial, a large, randomized, multi-center Phase 3 clinical study of vemurafenib in patients with previously untreated metastatic melanoma with the BRAFV600 mutation.

6 Jun 2011

Wrinkles and bone health: Connection

According to a new study, women who have severe skin wrinkles during the first few years of menopause also appear to have lower bone mineral density.

5 Jun 2011

Customizing targeted therapies to each tumor's molecular characteristics may effectively treat cancer

Customizing targeted therapies to each tumor's molecular characteristics, instead of a one-size-fits-all approach by tumor type, may be more effective for some types of cancer, according to research conducted by The University of Texas MD Anderson Cancer Center.

4 Jun 2011

Sanofi's semuloparin Phase III study data against venous thromboembolism presented at ASCO 2011

Sanofi US announced today results of the pivotal SAVE-ONCO study which demonstrated that, in cancer patients initiating a chemotherapy regimen, investigational semuloparin significantly reduced the risk of the composite of symptomatic-deep vein thromboembolism (DVT), non-fatal pulmonary embolism (PE) or venous thromboembolism (VTE)-related death by 64%, meeting the study primary endpoint.

4 Jun 2011

Study links loss of PTEN gene with patient's response to melanoma therapy

Genetic analysis of the tumors from patients with advanced melanoma can clue researchers in to how well patients will respond to a therapy that targets the growth-promoting protein called BRAF, a researcher from the Perelman School of Medicine at the University of Pennsylvania will report on Monday, June 6 at the annual meeting of the American Society of Clinical Oncology.

4 Jun 2011

Impax announces results of IPX066 ADVANCE-PD and APEX-PD Phase III study against Parkinson's

Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc., today announced that IPX066 ADVANCE-PD and APEX-PD Phase III clinical study data will be presented in Poster Sessions at the 15th International Congress of Parkinson's Disease and Movement Disorders Conference in Toronto, Canada, held from June 5 to June 9.

4 Jun 2011

U of A researchers try to combat heart disease in cancer patients

Researchers in the Faculty of Medicine & Dentistry are trying to reverse a devastating trend: cancer survivors developing cardiovascular disease, one of the top two killers in Canada.

4 Jun 2011

Scientists find way to protect kidney from cancer drug toxicity

Scientists may have a way to make the powerful cancer drug cisplatin less toxic to the kidneys and more effective against some cancers.

4 Jun 2011

Starving breast cancer cells of hedgehog significantly slows tumour growth and spread

While it is already known that breast cancer cells create the conditions for their own survival by communicating their needs to the healthy cells that surround them, Australian researchers have identified a new way of turning off that cellular cross talk.

4 Jun 2011

Recommendations on new cancer drug review process fall short in several ways: CCAC

While the Colorectal Cancer Association of Canada congratulates Quebec Health Minister Yves Bolduc on the recommendations of the report of the Working Group on the evaluation process of new anti cancer medications (Rapport du Groupe de travail sur le processus d'évaluation des médicaments anticancéreux) recently issued, the CCAC notes that the recommendations fall short in several important ways.

4 Jun 2011

Medical Condition News

Promising results from Exelixis' cabozantinib phase 2 trial against metastatic ovarian cancer

ImaginAb, GE Healthcare sign master research deal to develop new PET diagnostic imaging agents

GP journal focuses on mental health

Older adults with subclinical hyperthyroidism may face higher risk of dying

ImmunoGen's SAR3419 Phase I trial data on B-cell non-Hodgkin's lymphoma presented at ASCO 2011

Brown fat can treat obesity and diabetes

Alnylam's ALN-VSP Phase I trial data on liver cancer presented at ASCO 2011

Nonmenstruating female athletes have abnormal bone structure: Study

Bariatric weight-loss surgery may increase risk of fractures

Anti-ghrelin vaccine decreases food intake and increases calorie burning in mice

Positive results from Plexxikon's vemurafenib Phase 2 and 3 trial against metastatic melanoma

Wrinkles and bone health: Connection

Customizing targeted therapies to each tumor's molecular characteristics may effectively treat cancer

Sanofi's semuloparin Phase III study data against venous thromboembolism presented at ASCO 2011

Study links loss of PTEN gene with patient's response to melanoma therapy

Impax announces results of IPX066 ADVANCE-PD and APEX-PD Phase III study against Parkinson's

U of A researchers try to combat heart disease in cancer patients

Scientists find way to protect kidney from cancer drug toxicity

Starving breast cancer cells of hedgehog significantly slows tumour growth and spread

Recommendations on new cancer drug review process fall short in several ways: CCAC

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Latest News